Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Fischer-Riepe L, et al. Among authors: schambach a. Clin Cancer Res. 2024 Apr 9:OF1-OF14. doi: 10.1158/1078-0432.CCR-23-3157. Online ahead of print. Clin Cancer Res. 2024. PMID: 38593230
Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines.
Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, Sandalcioglu IE, Neyazi B, Moritz T, Meyer J, Rossig C, Altvater B, Eiz-Vesper B, Morgan MA, Abken H, Schambach A. Zimmermann K, et al. Among authors: schambach a. Cancers (Basel). 2020 Feb 6;12(2):375. doi: 10.3390/cancers12020375. Cancers (Basel). 2020. PMID: 32041222 Free PMC article.
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.
Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, Köhl U, Eiz-Vesper B, Esser R. Glienke W, et al. Among authors: schambach a. Front Immunol. 2022 Mar 24;13:839783. doi: 10.3389/fimmu.2022.839783. eCollection 2022. Front Immunol. 2022. PMID: 35401506 Free PMC article.
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Altvater B, Kailayangiri S, Spurny C, Flügge M, Meltzer J, Greune L, Urban K, Schwöppe C, Brand C, Schliemann C, Hintelmann H, Harrach S, Hartmann W, Abken H, Kuehle J, Schambach A, Görlich D, Berdel WE, Rossig C. Altvater B, et al. Among authors: schambach a. Cancer Gene Ther. 2023 Oct;30(10):1355-1368. doi: 10.1038/s41417-023-00642-x. Epub 2023 Jun 30. Cancer Gene Ther. 2023. PMID: 37391502 Free PMC article.
Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
Rudek LS, Zimmermann K, Galla M, Meyer J, Kuehle J, Stamopoulou A, Brand D, Sandalcioglu IE, Neyazi B, Moritz T, Rossig C, Altvater B, Falk CS, Abken H, Morgan MA, Schambach A. Rudek LS, et al. Among authors: schambach a. Front Immunol. 2021 Nov 3;12:751138. doi: 10.3389/fimmu.2021.751138. eCollection 2021. Front Immunol. 2021. PMID: 34804035 Free PMC article.
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Klöß S, Kloth C, Mangare C, Bonifacius A, Tischer-Zimmermann S, Blasczyk R, Maecker-Kolhoff B, Uchanska-Ziegler B, Abken H, Schambach A, Hudecek M, Eiz-Vesper B. Dragon AC, et al. Among authors: schambach a. J Immunother Cancer. 2020 Oct;8(2):e000736. doi: 10.1136/jitc-2020-000736. J Immunother Cancer. 2020. PMID: 33127653 Free PMC article.
358 results